BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Saxon JA, Sholl LM, Jänne PA. EGFR L858M/L861Q cis Mutations Confer Selective Sensitivity to Afatinib. J Thorac Oncol 2017;12:884-9. [PMID: 28088511 DOI: 10.1016/j.jtho.2017.01.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
Number Citing Articles
1 Yuan P, Huang S, Bao F, Cao J, Sheng H, Shi L, Lv W, Hu J. Discriminating association of a common telomerase reverse transcriptase promoter polymorphism with telomere parameters in non-small cell lung cancer with or without epidermal growth factor receptor mutation. European Journal of Cancer 2019;120:10-9. [DOI: 10.1016/j.ejca.2019.06.024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
2 Bejjanki H, Bishnoi R, Reisman D. Novel Mutation Pair L858M/L861Q Caused Resistance to Both First- and Third-Generation EGFR Inhibitors, but Was Found to Be Sensitive to the Combination of Lapatinib and Erbitux. J Thorac Oncol 2017;12:e169-70. [PMID: 28939152 DOI: 10.1016/j.jtho.2017.06.069] [Reference Citation Analysis]
3 Zhao Y, Zhu D, Gao J. Molecular analysis and systematic profiling of allosteric inhibitor response to clinically significant epidermal growth factor receptor missense mutations in non‐small cell lung cancer. J Chin Chem Soc 2021;68:2021-34. [DOI: 10.1002/jccs.202100217] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Castellano GM, Aisner J, Burley SK, Vallat B, Yu HA, Pine SR, Ganesan S. A Novel Acquired Exon 20 EGFR M766Q Mutation in Lung Adenocarcinoma Mediates Osimertinib Resistance but is Sensitive to Neratinib and Poziotinib. J Thorac Oncol 2019;14:1982-8. [PMID: 31254668 DOI: 10.1016/j.jtho.2019.06.015] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
5 Köhler J. Second-Line Treatment of NSCLC-The Pan-ErbB Inhibitor Afatinib in Times of Shifting Paradigms. Front Med (Lausanne) 2017;4:9. [PMID: 28243590 DOI: 10.3389/fmed.2017.00009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
6 Masood A, Kancha RK, Subramanian J. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer harboring uncommon EGFR mutations: Focus on afatinib. Semin Oncol 2019;46:271-83. [PMID: 31558282 DOI: 10.1053/j.seminoncol.2019.08.004] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 9.7] [Reference Citation Analysis]
7 Long X, Qin T, Lin J. Great Efficacy of Afatinib in a Patient with Lung Adenocarcinoma Harboring EGFR L833V/H835L Mutations: A Case Report. Onco Targets Ther 2020;13:10689-92. [PMID: 33116645 DOI: 10.2147/OTT.S260157] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Moran T, Taus A, Arriola E, Aguado C, Dómine M, Rueda AG, Calles A, Cedrés S, Viñolas N, Isla D, Palmero R, Sereno M, Diaz V, Juan O, Marsé R, Martorell PM, Sánchez Torres JM; Study Group for the Uncommon EGFR Mutations in Spain. Clinical Activity of Afatinib in Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Spanish Retrospective Multicenter Study. Clin Lung Cancer 2020;21:428-436.e2. [PMID: 32461037 DOI: 10.1016/j.cllc.2020.04.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
9 Kimura S, Tanaka K, Harada T, Liu R, Shibahara D, Kawano Y, Nakanishi Y, Okamoto I. Sensitivity of epidermal growth factor receptor with single or double uncommon mutations to afatinib confirmed by a visual assay. Cancer Sci 2018;109:3657-61. [PMID: 30255614 DOI: 10.1111/cas.13787] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
10 Zhang T, Wan B, Zhao Y, Li C, Liu H, Lv T, Zhan P, Song Y. Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment. Transl Lung Cancer Res 2019;8:302-16. [PMID: 31367543 DOI: 10.21037/tlcr.2019.04.12] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 10.3] [Reference Citation Analysis]
11 He SY, Lin QF, Chen J, Yu GP, Zhang JL, Shen D. Efficacy of afatinib in a patient with rare EGFR (G724S/R776H) mutations and amplification in lung adenocarcinoma: A case report. World J Clin Cases 2021; 9(6): 1329-1335 [PMID: 33644199 DOI: 10.12998/wjcc.v9.i6.1329] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
12 Wang S, Li J. Second-generation EGFR and ErbB tyrosine kinase inhibitors as first-line treatments for non-small cell lung cancer. Onco Targets Ther 2019;12:6535-48. [PMID: 31496745 DOI: 10.2147/OTT.S198945] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
13 Imamura F, Inoue T, Kunimasa K, Kubota A, Kuhara H, Tamiya M, Nishino K, Kimura M, Kuno K, Kawachi H, Kumagai T. Switching from first or second generation EGFR-TKI to osimertinib in EGFR mutation-positive NSCLC. Lung Cancer Manag 2020;9:LMT29. [PMID: 32346403 DOI: 10.2217/lmt-2020-0005] [Reference Citation Analysis]
14 Kohsaka S, Petronczki M, Solca F, Maemondo M. Tumor clonality and resistance mechanisms in EGFR mutation-positive non-small-cell lung cancer: implications for therapeutic sequencing. Future Oncol 2019;15:637-52. [PMID: 30404555 DOI: 10.2217/fon-2018-0736] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 8.5] [Reference Citation Analysis]
15 Levantini E, Maroni G, Del Re M, Tenen DG. EGFR signaling pathway as therapeutic target in human cancers. Semin Cancer Biol 2022:S1044-579X(22)00096-7. [PMID: 35427766 DOI: 10.1016/j.semcancer.2022.04.002] [Reference Citation Analysis]
16 Longo V, Catino A, Montrone M, Pizzutilo P, Pesola F, Marech I, Capone I, Prelaj A, Galetta D. Successful treatment of triple EGFR mutation T785A/L861Q/H297_E298 with afatinib. Thorac Cancer 2021;12:2031-4. [PMID: 34008923 DOI: 10.1111/1759-7714.13953] [Cited by in F6Publishing: 1] [Reference Citation Analysis]